FDA approves Baxter's hemophilia B therapy; Randal Kirk invests in AmpliPhi;

@FierceBiotech: Big Data guru Atul Butte's NuMedii scores $3.5M VC round for 'digital' drug research. FierceBiotech IT story | Follow @FierceBiotech

 @JohnCFierce: Stanley Family Foundation spearheads a $21M round for Heptares - (GPCRs). News | Follow @JohnCFierce

@RyanMFierce: J&J's pharma chairman lands 'more deals' in Boston innovation push. Report | Follow @RyanMFierce

> Baxter International announced that the FDA has approved Rixubis [Coagulation Factor IX (Recombinant)] for adults with hemophilia B. Release

> AmpliPhi BioSciences raised $7 million from a private placement of shares. The biotech is working on antibacterial therapies to treat drug resistant infections. Randal Kirk's Third Security was one of the investors. Release

> Seattle Genetics ($SGEN) has exercised an option to co-develop an additional antibody-drug conjugate under a collaboration deal it has with Agensys. Release

Pharma News

@FiercePharma: India suspends Actos on safety concerns. Two other (very old) drugs, too. Report | Follow @FiercePharma

@EricPFierce: FDA goes from passive to aggressive on compounders. I wonder how long before certain Congressmen complain. More | Follow @EricPFierce

@CarlyHFierce: Proxy fight heating up at Vivus... First Manhattan announces search for new CEO candidates. Yesterday's story | Follow @CarlyHFierce

> Pfizer, Amgen eye $1B deal for Russian biosimilars developer Biocad. Report

> Novo Nordisk steps away from now-controversial Paula Deen. Article

> Aspen feeds its global appetite with 2nd deal in a week. News

Medical Device News

@FierceMedDev: St. Jude takes to Japan with MRI-safe pacer. Story | Follow @FierceMedDev

@DamianFierce: For CROs big and small, you're only as good as your reputation. The view from  DIA 2013. Editor's corner | Follow @DamianFierce

@MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Report | Follow @MichaelGFierce

> Medtronic warns over pump tied to 14 deaths. Story

> Navidea keys up Alzheimer's Dx agent for Phase III. News

Pharma Manufacturing News

> Aspen, Merck deal includes API plants in U.S., Netherlands. Article

> Roche sets out strict expectations for contractors. Report

> Drugmakers more concerned with quality than price in picking CMOs. Item

> FDA spells out its expectations for crude heparin. More

Vaccines News

> Japan faces vaccine shortage in struggle to control rubella. Report

> ACIP rules on GSK, Novartis and Sanofi vaccines. Story

> Corruption alleged as Indian vaccine shortage continues. Item

> Type 1 diabetes vaccine impresses in early study. News

> Takeda tackling norovirus in bid to grow vaccine biz. Article

And Finally… A new study helps explain how parts of the brain maintain their balance of zinc, an element required in small but crucial doses. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.